Rafferty Asset Management
CRBP icon

Rafferty Asset Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Rafferty Asset Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-34,039
Closed -$702K – 1149
2024
Q3 		$702K Buy
34,039
+10,827
+47% +$554K ﹤0.01% 868
2024
Q2 		$1.05M Buy
+23,212
New +$976K ﹤0.01% 811
2020
Q4 		– Sell
-20,795
Closed -$1.12M – 1019
2020
Q3 		$1.12M Buy
20,795
+19,732
+1,856% +$3.57M 0.01% 565
2020
Q2 		$268K Buy
+1,063
New +$215K ﹤0.01% 857

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rafferty Asset Management's CRBP Position: Q4 2024 in Review

Rafferty Asset Management sold out of Corbus Pharmaceuticals (CRBP) in Q4 2024, closing a stake of 34,039 shares — an estimated $702K sold.

Rafferty Asset Management first reported a position in CRBP in Q2 2020 and held it in 4 quarters. The position peaked at $1.12M in Q3 2020. 99 funds tracked by Wall St. Rank hold CRBP as of Q4 2024.

  • Rafferty Asset Management reported no remaining Corbus Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Rafferty Asset Management sold 34,039 Corbus Pharmaceuticals shares in Q4 2024, an estimated $702K.
  • Rafferty Asset Management first reported a position in Corbus Pharmaceuticals in Q2 2020 and held it in 4 quarters.
  • Rafferty Asset Management's Corbus Pharmaceuticals position peaked at $1.12M in Q3 2020.
  • 99 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2024.

Based on Rafferty Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.